Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2015
Summary
Global Markets Directs, Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2015, provides an overview of the Opioid-Induced Constipation (OIC)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Opioid-Induced Constipation (OIC) Overview 7
Therapeutics Development 8
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 8
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 9
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Opioid-Induced Constipation (OIC) - Products under Development by Companies 12
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 13
AstraZeneca Plc 13
Cosmo Pharmaceuticals S.p.A 14
Ironwood Pharmaceuticals, Inc. 15
Shionogi & Co., Ltd. 16
Sucampo Pharmaceuticals, Inc. 17
Synergy Pharmaceuticals, Inc. 18
Valeant Pharmaceuticals International, Inc. 19
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(axelopran sulfate + oxycodone hydrochloride) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
axelopran sulfate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dolcanatide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
linaclotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lubiprostone - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
methylnaltrexone bromide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
naldemedine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
naloxegol oxalate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
naloxone hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 47
Opioid-Induced Constipation (OIC) - Dormant Projects 67
Opioid-Induced Constipation (OIC) - Discontinued Products 68
Opioid-Induced Constipation (OIC) - Product Development Milestones 69
Featured News & Press Releases 69
Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 69
Jun 24, 2015: Shionogi Announces That Naldemedine Met the Primary Endpoint in Its First Japanese Phase 3 Study for the Treatment of Opioid - Induced Constipation in Cancer Patients 69
Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation 69
May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 70
May 16, 2015: MOVANTIK (naloxegol) Safety Analyses of Opioid-Induced Constipation Patients 65 and Older with Chronic Non-Cancer Pain 70
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 72
Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 72
Apr 02, 2015: Nektar Announces Receipt of $100 Million Milestone Payment from AstraZeneca 73
Mar 31, 2015: MOVANTIK (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US 73
Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76
List Of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca Plc, H2 2015 13
Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 14
Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015 15
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H2 2015 16
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015 17
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H2 2015 18
Opioid-Induced Constipation (OIC) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Assessment by Combination Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H2 2015 47
Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2015 67
Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2015 68
List Of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Top 10 Targets, H2 2015 22
Number of Products by Stage and Top 10 Targets, H2 2015 22
Number of Products by Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Top 10 Routes of Administration, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
Number of Products by Top 10 Molecule Types, H2 2015 28
Number of Products by Stage and Top 10 Molecule Types, H2 2015 28
